PULMONARY
HYPERTENSION
Your trial CORE-powered
HYPERLIPIDEMIA
HYPERTENSION
heart failure
Acute Coronary Syndrome
IQVIA is the leader in conducting large cardiovascular outcomes trials where long-term patient retention is critical.
We followed 25,000 ACS patients in outcomes trials in the last 10 years.
THE PROOF
Heart Failure
IQVIA knows how to meet the challenges of enrolling patients in an acute setting and follow-up of chronic outcomes including ADHF, HFrEF, and HFpEF.
THE PROOF
Hypertension
IQVIA brings extensive hypertension regulatory expertise and a team experienced in phase I-IV trial delivery.
Our Connected Devices platform includes blood pressure, ECG, and other wearables for near-real time cardiac monitoring in traditional and virtual clinical trials.
THE PROOF
50
%
increase in
enrollment
Through our Connected Intelligence approach to cardiovascular development, IQVIA can help you rethink old challenges and surround your trials with a proven suite of capabilities to help you reach milestones faster, deliver programs within budget, and bring game-changing therapies to patients sooner.
Click each area to learn more
ACUTE CORONARY SYNDROME
ATRIAL FIBRILLATION
IQVIA brings extensive experience in PAH and relationships with renowned KOLs in the US and Europe.
Our highly specialized Clinical Trial Educators can support recruitment for the most challenging trials.
THE PROOF
Connected approach to your cardiovascular trials
Atrial Fibrillation (Afib)
IQVIA has conducted 12 trials in arrhythmia and Afib involving 41,000 patients over the last 10 years including large outcomes trials.
THE PROOF
In a large stroke prevention outcome trial, IQVIA achieved 0.005% lost to follow-up and <1.2% withdrawn consent
patient
follow-up
achieved
patient
follow-up
achieved
of FDA-approved heart failure drugs
faster screening and randomization
PULMONARY
HYPERTENSION
HYPERLIPIDEMIA
HYPERTENSION
HEART FAILURE
ACUTE CORONARY SYNDROME
ATRIAL FIBRILLATION
PULMONARY
HYPERTENSION
HYPERLIPIDEMIA
HYPERTENSION
HEART FAILURE
ACUTE CORONARY SYNDROME
ATRIAL FIBRILLATION
Hyperlipidemia
IQVIA’s teams leverage our global network of experienced research sites and relationships with leading academic research organizations (AROs) to successfully deliver hyperlipidemia therapy studies.
THE PROOF
A phase III randomized double blinded placebo-controlled PAH study when supported by IQVIA Clinical Trial Educators
Hyperlipidemia clinical trials conducted by IQVIA in the last 10 years
IQVIA was involved with 100% of FDA-approved heart failure drugs between 2011 and 2019
Average of 1.7% of patients lost to follow-up (LTFU) and withdrawn consent in ACS outcomes trials in last 10 years
21
trials
19,000
patients
Pulmonary Arterial Hypertension (PAH)
Cardiovascular trials
Through our CORE-powered approach to cardiovascular development, IQVIA can help you rethink old challenges and surround your trials with a proven suite of capabilities to help you reach milestones faster, deliver programs within budget, and bring game-changing therapies to patients sooner.
HYPERTENSION
HEART FAILURE
ACUTE CORONARY SYNDROME
ATRIAL FIBRILLATION
< BACK
< BACK
< BACK
< BACK
< BACK
< BACK
Cardiovascular trials
Cardiovascular trials
Cardiovascular trials
Cardiovascular trials
Cardiovascular trials